Colorectal cancer costing Europe €19.1bn, Belfast-led research finds

Colorectal cancer costing Europe €19.1bn, Belfast-led research finds
Queen’s University in Belfast (Liam McBurney/PA)

Colorectal cancer is costing Europe some €19.1 billion a year, new research led by the Queen’s University Belfast has found.

The figure includes direct expenditure as well as indirect costs including premature death and sick leave.

Colorectal cancer, described as the second leading cause of cancer death in Europe, claims one European life every three minutes.

The new research, published in high impact journal Lancet Gastroenterology and Hepatology, also highlights the significant inequalities that European colorectal cancer patients experience, depending on where they live and how a higher spend on cancer drugs than on hospital care, did not always lead to better patient outcomes.

The research found the economic cost of colorectal cancer in Europe to be €19.1 billion.

This figure breaks down into direct expenditure on colorectal cancer care in Europe to €7.5 billion, just under 40% of the total cost.

The indirect economic impact, which measures the costs of premature death, temporary and permanent absence from work, and unpaid informal care, was €11.6 billion, over 60% of the total cost.

Senior author on the paper, Mark Lawler, professor of digital health at Queen’s University Belfast, warned a lack of investment in screening and early diagnosis has created an “economic time bomb”.

“Our research highlights the enormous impact that colorectal cancer has, not only on the health of our citizens, but also increasingly on the financial prosperity of patients, their families, health systems and economies,” he said.

“By not investing appropriately in services such as screening, early diagnosis and treatment, we have created an economic time bomb that is placing an untenable burden on our health systems and on society.

“It’s not what you spend, it’s the way that you spend it.

“We must ensure that we use our precious healthcare resources in a way that ensures better outcomes for patients but delivered with cognisance of the financial pressures that health systems currently face, particularly in the context of Covid.”

The research also found a wide variation in the economic burden of colorectal cancer across Europe.

Countries with similar gross domestic product (GDP) per head of population had widely varying health-care expenditures on colorectal cancer, leading to significant inequalities for colorectal cancer patients, depending on where they live in Europe.

Expenditure on cancer drugs was found to have increased by over 200% on average over a six-year period, but was not necessarily associated with better outcomes.

Ireland is among several central and western European countries that had significantly increased spend on cancer drugs - Ireland (+473%) as well as Austria (+369%). This was mostly due to increases in the use of targeted cancer drugs.

Declan French, professor of finance from Queen’s Management School and co-author of the study, added: “This is a very important piece of work on a common cancer with significant implications for the financing of health systems.

“It highlights how transdisciplinary cross-faculty research, bringing together expertise in finance and health from across the University, can give unique insights into health spending that can influence health policy and potentially enhance patient care.”

More in this section

IE_180_logo
Price info

Subscribe to unlock unlimited digital access.
Cancel anytime.

Terms and conditions apply

Puzzles logo
IE-logo

Puzzles hub

Visit our brain gym where you will find simple and cryptic crosswords, sudoku puzzles and much more. Updated at midnight every day. PS ... We would love to hear your feedback on the section right HERE.

Puzzles logo
IE-logo

Puzzles hub

Visit our brain gym where you will find simple and cryptic crosswords, sudoku puzzles and much more. Updated at midnight every day. PS ... We would love to hear your feedback on the section right HERE.